We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





COVID-19 Molecular Diagnostics Fueling Growth of Global Infectious Disease In-Vitro Diagnostics Market

By LabMedica International staff writers
Posted on 30 Apr 2021
The global infectious disease in-vitro diagnostics market is projected to record promising growth over the 2020-2030 period on back of the rising prevalence of infectious diseases around the world, particularly COVID-19.

These are the latest findings of TMR Research (San Francisco, CA, USA), a provider of customized market research and consulting services. More...


Infectious disease in-vitro diagnostic tests perform the function of detecting and identifying the specific infectious agent to establish its origin and enable healthcare professionals to provide the ideal treatment to a patient. These tests can also help in overcoming potential epidemics. This is acting as a vital growth generator for the infectious disease in-vitro diagnostics market. The increasing incidences of infectious diseases and the growing need to tackle them at an early stage have led to tremendous advancements in terms of diagnostics. Infectious disease in-vitro diagnostics is one of them. Thus, this will bring good growth opportunities for the infectious disease in-vitro diagnostics market.

The overwhelming use of infectious disease in-vitro diagnostics in point-of-care testing, central laboratories and others will create immense growth prospects for the market. The growing influence of infectious disease in-vitro diagnostics in detecting a variety of infections such as respiratory viruses, Chlamydia, HPV, Gonorrhea, Clostridium Difficile, MRSA, Streptococcus, Hepatitis B, HIV, Hepatitis C, COVID-19, and others will serve as a vital growth-generator.

The COVID-19 pandemic has wreaked havoc across the globe due to the rising transmission rates and fatality rates. The most efficient way to decrease the mortality rate and prevent infecting others is an intense focus on testing. For COVID-19 testing, RT-PCR (real-time reverse transcription-polymerase chain reaction) is regarded as a gold standard. This testing method is the clinical gold standard for the etiological diagnosis of COVID-19 in which viral DNA is directly detected. RT-PCR tests are being considered as the best option for COVID-19 testing around the world. The growing popularity of these testing methods will create huge growth prospects for the infectious disease in-vitro diagnostics market.

Manufacturers in the infectious disease in-vitro diagnostics market are developing kits that are easier for home use. These kits are designed for home-testing and treatments. Self-testing kits are useful for early diagnosis and consistent patient monitoring. They are also important for curbing costs. Hence, the rising demand for self-testing kits is directly proportional to the growth of the infectious disease in-vitro diagnostics market.

Geographically, North America will continue to dominate the global infectious disease in-vitro diagnostics market with the largest share between 2020 and 2030 on the back of the rising COVID-19 infections across the region. However, the Asia Pacific infectious disease in-vitro diagnostics market is expected to record the fastest growth during this period.

Related Links:
TMR Research


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.